CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- 4 Open-market buy CEO and CFO bought 9,250 shares at $8.35 ($77,238)
- 4 Open-market buy CEO and CFO bought 6,774 shares at $7.38 ($49,992)
- 10-Q Report Quarterly Report
- NT 10-Q Other NT 10-Q
- 4 Open-market buy Chief Medical Officer bought 1,000 shares at $16.25 ($16,250)
- 4 Open-market buy CEO and CFO bought 6,000 shares at $16.09 ($96,540)
- 4 Open-market buy CEO and CFO bought 6,000 shares at $16.74 ($100,440)
- 4 Open-market buy VP Clinical Reg Affairs bought 500 shares at $16.74 ($8,370)
- EFFECT Other Notice of Effectiveness
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-3/A Offering Registration Statement
- UPLOAD Other SEC-generated Letter
- S-3 Offering Registration Statement
- 10-K Report Annual Report
- 4 Open-market buy CEO and CFO bought 5,500 shares at $19.80 ($108,900)
- 4 Open-market buy CEO and CFO bought 5,000 shares at $19.59 ($97,950)
- 4 Open-market buy VP Clinical Reg Affairs bought 500 shares at $18.47 ($9,235)
- 4 Open-market buy VP Clinical Reg Affairs bought 500 shares at $16.33 ($8,165)
- 4 Open-market buy Director bought 300 shares at $16.32 ($4,896)
- 4 Open-market buy VP Clinical Reg. Affairs bought 500 shares at $18.87 ($9,435)
Page 9 of 14 · 279 filings